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Abstract
Objective: The aim of this study was to explore the role of nasopharynx 
(NP) invasion alone in tonsillar carcinoma.
Materials and Methods: From 1987 to 2005, 32 patients with unresect-
able cT4b tonsillar carcinoma were retrospectively divided into two groups: 
the NP-only group, that included 11 patients with NP invasion alone without 
fitting other T4 criteria; and the other-T4b group, that included the remaining 
21 patients. Local control and overall survival were the main endpoints of 
interest.
Results: At the time of this analysis, 28 patients had died, with a median 
follow-up time for all 32 patients of 13 months (range, 1–228 months). The 
mean follow-up period for the four living patients was 180 months (range, 
125–228 months). When compared with the other T4b patients, patients 
with NP invasion alone, without fitting other T4 criteria, had greater 5-year 
local control (63.6% vs. 14.3%, p = 0.026; hazard ratio for local failure, 
0.31; 95% confidence interval, 0.11–0.94) and 5-year overall survival 
(45.5% vs. 10.3%, p = 0.022; hazard ratio for death from any cause, 0.34; 
95% confidence interval, 0.13–0.89).
Conclusion: In patients with tonsillar carcinoma, nasopharynx invasion 
alone should not be considered as an independent criterion of T4b clas-
sification in the next version of cancer staging. [Tzu Chi Med J 2009;
21(3):204–209]
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1. Introduction
Treating patients with unresectable tonsillar carci-
noma is clinically challenging. For these patients, two 
treatment modalities are available for potential cure: 
definitive radiotherapy (RT) and concurrent chemo-
radiotherapy (CCRT) [1,2]. In general, definitive CCRT 
is the treatment of choice for patients who are medi-
cally fit, and RT alone is the alternative for patients 
who are not [1]. Even if CCRT can be performed, 
however, treatment outcomes are eventually unsatis-
factory and overall survival is often short in these 
patients [2,3].
Most head and neck surgeons would agree that 
achieving adequate surgical margins is technically 
difficult for patients with tonsillar carcinoma with na-
sopharynx (NP) invasion. Thus, the clinical finding of 
NP invasion independently indicates a potentially un-
resectable disease (i.e. cT4b classification) and im-
plies a poor clinical outcome in accordance with the 
American Joint Committee on Cancer (AJCC) staging 
systems [4,5]. In our clinical practice, however, we 
observed some patients with NP invasion alone, who 
did not fit other T4 criteria, had good disease con-
trol, and long survival after definitive RT or CCRT. 
This observation raises a clinical question of whether 
these patients really have as poor clinical outcomes 
as the other cT4b patients; this question has not been 
well explored.
The aim of this retrospective case-series study 
was to clarify the following clinical question: should 
tonsillar carcinoma patients with NP invasion alone 
be classified independently and absolutely as a T4b 
disease? We challenged the primarily null hypothesis 
that there are similar clinical outcomes between pa-
tients with NP invasion alone and other T4b patients. 
Treatment outcomes, chiefly local control and over-
all survival, were defined as the study endpoints.
2. Materials and methods
2.1. Study design and endpoints
We retrospectively included 32 patients who had his-
tologically-proven unresectable cT4b tonsillar carci-
noma and who were treated with definitive RT or 
CCRT (Fig. 1) from January 1987 through December 
2005. All patients had undergone both endoscopy 
for the upper respiratory tract and cross-section im-
aging (computed tomography, magnetic resonance 
imaging, or both) of the head and neck region to de-
fine their locoregional disease extension. Cancer stages 
were retrospectively defined in accordance with the 
AJCC staging manual, 6th edition [4]. According to 
inclusion criteria as described below, these 32 pa-
tients were divided into the following two groups: the 
NP-only group, 11 patients with NP invasion alone 
Included (n = 32)
(unresectable T4b disease treated with definitive RT or CCRT)
Histologically-proven tonsillar carcinoma patients (n = 141)
Lost to follow-up (n = 0)
Analyzed (n = 11)
Lost to follow-up (n = 0)
Analyzed (n = 21)
NP invasion alone without
fitting other T4 criteria
The other T4b patients
The other-T4b group (n = 21)The NP-only group (n = 11)
• Died before analysis (n = 21)
• Died due to disease (n = 19)
• Died due to intercurrent
 disease (n = 2)
• Disease failure (n = 19)
• Local failure (n = 18)
• Locoregional failure (n = 18)
• Distant failure (n = 8)
• M1 disease (n = 13)
• T1–3 disease (n = 63)
• T4a disease (n = 31)
• T4b but treated with
 inadvertent surgery (n = 1)
• T4b but treated inadequately
 (RT dose < 45 Gy) (n = 1)
• Died before analysis (n = 7)
• Died due to disease (n = 5)
• Died due to intercurrent
 disease (n = 2)
• Disease failure (n = 7)
• Local failure (n = 4)
• Locoregional failure (n = 6)
• Distant failure (n = 3)
Excluded (n = 109)
Fig. 1 — Patient allocation diagram. RT = radiotherapy; CCRT = concurrent chemoradiotherapy; NP = nasopharynx.
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(without other T4 criteria); and the other-T4b group, 
the other 21 patients. Table 1 shows no clinically 
meaningful differences between the two groups in 
baseline characteristics. Tables 2 and 3 show indi-
vidual patient profiles of the two groups. The proce-
dures followed were in accordance with the ethical 
standards of the committee on human experimenta-
tion of the institution and with the Helsinki Declaration 
of 1975, as revised in 1983.
In the NP-only group, all 11 patients met the follow-
ing three criteria: (I) histologically-proven squamous-cell 
or undifferentiated carcinomas of the faucial tonsil; 
(II) treated with definitive RT or CCRT, with a minimum 
cumulative RT dose of 54 Gy; and (III) classified as a 
T4b disease due to NP invasion alone without other 
T4 criteria. In the other-T4b control group, potential 
candidates fitted the above criteria, from (I) to (II), 
but did not fit the third criterion, (III).
Local control and overall survival were the main 
endpoints of interest. Locoregional control, disease-
free survival, distant metastasis-free survival, and 
disease-specific survival were also recorded and 
analyzed as study endpoints.
2.2. Data collection and follow-up
We reviewed data from the cancer registry database, 
clinical images, and all original medical charts. 
Discrepancies were resolved by consensus. The last 
follow-up was recorded on the basis of the last pa-
tient visit at the institution, the last telephone inter-
view, or date of death. No patient was lost to follow-up. 
Follow-up time intervals were every 1–3 months during 
the first year after completion of RT, every 3–6 months 
during the 2nd–5th year, and every 6–12 months 
thereafter.
2.3. Treatment modality and policy
Radiotherapy was given for all 32 patients: definitive 
RT, n = 26; and definitive CCRT, n = 6. No formal treat-
ment policy existed during the time span of this 
study. Whether definitive RT or CCRT was actually 
conducted depended on the patient’s age, perform-
ance status, associated comorbidities, physician’s 
preference and—more importantly—the patient’s 
choice. The RT technique used in these two groups 
was the same; conventional RT with bilateral-opposed 
Table 2 — Individual patient profiles in the NP-only group
Patient no.
 Age (yr)/ Cancer stage Revised cancer  Local Locoregional Distant  Follow-up Final
 sex (AJCC 2002) stage* failure failure failure time† (mo) status
NP-1 62/M T4bN2c, IVB T3N2c, IVA Y Y Y  1 DOD
NP-2 63/M T4bN1, IVB T3N1, III Y Y N  2 DOD
NP-3 67/M T4bN3, IVB T3N3, IVB Y Y Y  6 DOD
NP-4 68/M T4bN0, IVB T3N0, III N N Y  12 DOD
NP-5 60/M T4bN3, IVB T3N3, IVB Y Y N  13 DOD
NP-6 81/F T4bN0, IVB T3N0, III N N N  40 DOD
NP-7 47/M T4bN2b, IVB T3N2b, IVA N Y N 125 AWD
NP-8 59/M T4bN0, IVB T3N0, III N N N 138 DOD
NP-9 56/F T4bN2b, IVB T3N2b, IVA N N N 144 AWD
NP-10 22/M T4bN2b, IVB T3N2b, IVA N N N 216 AWD
NP-11 22/F T4bN2b, IVB T3N2b, IVA N Y N 228 AWD
*Revised cancer stage from AJCC 2002, assuming that NP invasion alone is not an independent criterion in the T4b classification; †time inter-
val from completion of radiotherapy to death from any cause or to the last follow-up. NP = nasopharynx; AJCC = American Joint Committee on 
Cancer; M = male; F = female; Y = yes; N = no; DOD = died of disease; AWD = alive with disease.
Table 1 — Patient characteristics according to study 
group
 Patients, n (%)
 NP-only Other-T4b 
Total 
 group group  
p
Age (yr)    0.39
 > 50 8 (72.7) 12 (57.1) 20 (62.5)
 ≤ 50 3 (27.3) 9 (42.9) 12 (37.5)
Sex    0.07
 Male 8 (72.7) 20 (95.2) 28 (87.5)
 Female 3 (27.3) 1 (4.8) 4 (12.5)
T classification    *
 T4b 11 (100) 21 (100) 32 (100)
N classification     0.45
 N0–1 4 (36.4) 5 (23.8) 9 (28.1)
 N2–3 7 (63.7) 16 (76.2) 23 (71.9)
Stage     *
 IVB 11 (100) 21 (100) 32 (100)
Histology    0.71
 Grade 1–2 5 (45.5) 11 (52.4) 16 (50.0)
 Grade 3–4 6 (54.5) 10 (47.6) 16 (50.0)
Treatment    0.95
 RT  9 (81.8) 17 (81.0) 26 (81.3)
 CCRT 2 (18.2) 4 (19.0) 6 (18.8)
*p could not be calculated. NP = nasopharynx; RT = radiotherapy; 
CCRT = concurrent chemoradiotherapy.
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cone-down portals encompassed the primary tumor 
and bilateral upper neck. The median RT dose to the 
primary gross tumor was as follows: definitive RT, 
68.0 Gy with a range of 63.0–82.8 Gy; and, CCRT, 
73.8 Gy with a range of 59.4–79.2 Gy. No brachytherapy 
or intraoral cone boost was used. A single anterior-
posterior portal with a dose of 45–50 Gy was used 
for the lower neck irradiation down to the bilateral 
supraclavicular fossae. Cisplatin alone was given 
concurrently with RT for patients treated with CCRT. 
Dose regimens of cisplatin ranged from 60 to 
100 mg/m2 every 21–28 days during RT. The median 
cycle of cisplatin was 2 (range, 1–3).
2.4. Definition
We defined the study endpoints as follows: local/
locoregional failure, persistent local/locoregional 
disease 3 months after completion of RT, or local/
locoregional recurrence after a disease-free time in-
terval; distant failure, cancer failure at distant sites; 
disease failure, cancer failure at any site; and overall 
survival, the time interval from completion of RT to 
death from any cause or to the last follow-up.
2.5. Statistical analyses
We used commercial statistical software (SPSS version 
10.0; SPSS Inc., Chicago, IL, USA) to conduct statistical 
analyses as follows: the Kaplan-Meier method to cu-
mulatively estimate survival and disease-control rates; 
the log-rank test to assess curve difference between 
groups; Pearson’s χ2 test to evaluate differences be-
tween variables; and Cox proportional hazard regres-
sion to perform multivariate analyses for hazard ratio 
(HR) assessment. For estimating the effective size, 
HR was provided with a 95% confidence interval (CI) 
in addition to a conventional p value. All tests were 
two-tailed and considered to be statistically significant 
when p < 0.05.
3. Results
3.1. Patients
At the time of our analysis, 28 patients died. The me-
dian follow-up time for all 32 patients was 13 months 
(range, 1–228 months) and for the four living patients 
was 180 months (range, 125–228 months; all in the 
NP-only group). There were 28 men and four women, 
with a median age of 60 years (range, 22–81 years).
3.2. Disease control and survival
Five-year local control rates by groups were 63.6% in 
the NP-only group and 14.3% in the other-T4b group, 
p = 0.026 (Fig. 2). In addition, we found an HR for local 
failure of 0.31 (95% CI, 0.11–0.94) in the NP-only 
Table 3 — Individual patient profiles in the other-T4b group
Patient no.
 Age (yr)/ Cancer stage Revised cancer  Local Locoregional Distant  Follow-up Final
 sex (AJCC 2002) stage* failure failure failure time† (mo) status
nNP-1 36/M T4bN3, IVB T4bN3, IVB Y Y N  2 DOD
nNP-2 47/M T4bN2b, IVB T4bN2b, IVB Y Y Y  3 DOD
nNP-3 66/M T4bN2b, IVB T4bN2b, IVB Y Y Y  3 DOD
nNP-4 51/F T4bN1, IVB T4bN1, IVB Y Y N  6 DOD
nNP-5 53/M T4bN2b, IVB T4bN2b, IVB Y Y N  6 DOD
nNP-6 44/M T4bN3, IVB T4aN3, IVB Y Y Y  8 DOD
nNP-7 36/M T4bN2b, IVB T4bN2b, IVB Y Y N  9 DOD
nNP-8 78/M T4bN0, IVB T4bN0, IVB Y Y N 10 DOD
nNP-9 62/M T4bN2b, IVB T4bN2b, IVB Y Y Y 10 DOD
nNP-10 65/M T4bN2c, IVB T4bN2c, IVB Y Y N 13 DOD
nNP-11 65/M T4bN0, IVB T4bN0, IVB Y Y N 13 DOD
nNP-12 38/M T4bN0, IVB T4bN0, IVB Y Y N 13 DOD
nNP-13 69/M T4bN3, IVB T4bN3, IVB Y Y N 13 DOD
nNP-14 44/M T4bN2c, IVB T4aN2c, IVA Y Y Y 15 DOD
nNP-15 71/M T4bN3, IVB T4bN3, IVB Y Y Y 15 DOD
nNP-16 46/M T4bN2b, IVB T4bN2b, IVB Y Y N 15 DOD
nNP-17 81/M T4bN0, IVB T4bN0, IVB Y Y Y 16 DOD
nNP-18 42/M T4bN2c, IVB T4bN2c, IVB Y Y N 19 DOD
nNP-19 44/M T4bN2b, IVB T4bN2b, IVB N N Y 62 DOD
nNP-20 66/M T4bN2b, IVB T4bN2b, IVB N N N 70 DID
nNP-21 68/M T4bN2c, IVB T4bN2c, IVB N N N 72 DID
*Revised cancer stage from AJCC 2002, assuming that NP invasion alone is not an independent criterion in the T4b classification; †time interval 
from completion of radiotherapy to death from any cause or to the last follow-up. AJCC = American Joint Committee on Cancer; NP = nasopharynx; 
M = male; F = female; Y = yes; N = no; DOD = died of disease; DID = died of intercurrent disease.
208 TZU CHI MED J  September 2009  Vol 21  No 3
group when compared with the other-T4b group. 
Treatment modalities, namely definitive RT versus 
CCRT, had no statistically significant impact on the 
local control (29.6% vs. 33.3%, p = 0.92).
Five-year overall survivals were 45.5% in the NP-
only group and 10.3% in the other-T4b group 
(p = 0.022; Fig. 3). We observed an HR for death from 
any cause of 0.34 (95% CI, 0.13–0.89) in the NP-only 
group when compared with the other-T4b group. In 
addition, five patients in the NP-only group had their 
survival time of more than 10 years, but no patients 
in the other-T4b group had such a long survival. The 
statistical significance on local control, however, did 
not translate into locoregional control and disease-
free survival, as shown in Table 4.
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Fig. 2 — Kaplan-Meier estimates of local control accord-
ing to study groups: the NP-only group included patients 
with NP invasion alone and the other-T4b group included 
the other T4b patients. NP = nasopharynx.
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Fig. 3 — Kaplan-Meier estimates of overall survival ac-
cording to study groups: the NP-only group included pa-
tients with NP invasion alone and the other-T4b group 
included the other T4b patients. NP = nasopharynx.
3.3. Salvage treatments
At the time of our analysis, 26 patients had disease 
failures: seven in the NP-only group and 19 in the 
other-T4b group (Fig. 1). For the 11 patients who failed 
with a component of distant metastases, only palliative 
treatments were given: three in the NP-only group and 
eight in the other-T4b group. For the other 15 patients 
who failed without distant metastases, salvage treat-
ments were given as follows: three re-irradiation and 
one palliative treatment in the NP-only group; and, 
four salvage re-irradiation and seven palliative treat-
ments in the other-T4b group. Palliative treatments 
included best supportive care, low-dose chemotherapy, 
and low-dose re-irradiation (i.e. re-RT dose < 45 Gy). 
For the four patients who died due to causes other 
than cancer disease, the causes of death were as fol-
lows: one falling injury with lethal intracranial hemor-
rhage, one myocardial infarction, one traffic accident, 
and one acute cerebral vascular infarction.
4. Discussion
Poor local control and short overall survival are the 
hallmarks of unresectable cT4b tonsillar carcinoma 
[6]. In this study, when compared with the other cT4b 
patients, patients with NP invasion alone, without fit-
ting other cT4 criteria, had better 5-year local control 
(63.6% vs. 14.3%, p = 0.026; HR for local failure, 
0.31; 95% CI, 0.11–0.94) and 5-year overall survival 
(45.5% vs. 10.3%, p = 0.022; HR for death from any 
cause, 0.34; 95% CI, 0.13–0.89). The findings opposed 
the primary null hypothesis and strongly suggest that 
the clinical factor of NP invasion alone should be re-
considered as an independent criterion of T4b dis-
ease in tonsillar carcinoma.
Death from any cause is one event with a solid 
endpoint in oncology investigations. In this study, we 
observed a better 5-year overall survival in patients 
with NP invasion alone than in the other T4b pa-
tients. In addition, five patients in the NP-only group 
had survival times of more than 10 years, but no 
patient in the other-T4b group had such long survival 
times. These findings suggest that patients with NP 
invasion alone may behave differently from the other 
cT4b patients.
The T classification is clinically useful to represent 
local cancer burden in patients with tonsillar carci-
noma [4,5]. Our study, however, hinted at a possible 
pitfall of the T classification (i.e. heavily constructed 
on the basis of anatomic cancer extension). Some 
anatomic cancer extensions, such as NP invasion, 
could be ominous signs for patients treated with pri-
mary surgery, but may not be so clinically meaningful 
for patients treated with definitive RT or CCRT. This 
limitation has been presented in a prior study that 
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suggested the quantitative primary tumor volume is 
a better factor than the T classification in terms of 
estimating local cancer burden [7]. Our study results 
confirmed this limitation of the T classification.
In most head and neck cancers, including tonsillar 
carcinoma, the T classification has its primary role in 
predicting local control [8]. In our previously pub-
lished data on tonsillar carcinoma, we found 5-year 
local control rates of 78% in T1–3 patients and 32% 
in T4a patients [9]. In the present study, in patients 
with NP invasion alone, we observed a 5-year local 
control rate of 63.6%, which is much higher than the 
32% reported in T4a patients. This observation also 
suggested that patients with NP invasion alone be-
haved differently from the other T4 patients.
For unresectable oropharyngeal carcinoma pa-
tients, including tonsillar carcinoma patients, CCRT 
has shown better treatment outcomes than defini-
tive RT [2,3,10]. For that reason, in these locally ad-
vanced patients, CCRT is the treatment of choice if the 
patient is medically fit. Our data, however, did not 
show this treatment benefit in CCRT. This may be 
due to inevitable selection bias and rare CCRT cases 
(n = 6) in this study.
This study had several limitations. Two main limi-
tations were the retrospective study design and the 
small number of cases examined; thus, the conclu-
sions of this study should be confirmed by further 
investigations. Despite these limitations, this study 
showed that patients with NP invasion alone had better 
clinical outcomes, in terms of local control and over-
all survival, than the other T4b patients. Our obser-
vation, therefore, is a hint for revising future cancer 
staging systems in patients with tonsillar carcinoma.
In conclusion, for unresectable tonsillar carcinoma, 
patients with NP invasion alone had better clinical 
outcomes than the other T4b patients. Thus, for 
these patients, nasopharynx invasion alone should 
not be reconsidered to be an independent criterion 
of T4b classification in the next version of cancer 
staging.
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Disease-free survival 36.4  9.5 0.11 0.49 0.20–1.17 0.25
DM-free survival  70.0 40.4 0.45 0.60 0.16–2.29 0.66
Disease-specific survival 54.6 14.3 0.07 0.39 0.15–1.07 0.09
*p values calculated by log-rank test; †p values calculated by Cox proportional hazard regression method. NP = nasopharynx; T4b = T4b classification; 
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